Genentech, Inc.

Newlink Genetics Corporation

National Institute of Biological Sciences, Beijing

F. Hoffmann-la Roche Ag

Zhuhai Yufan Biotechnologies Co., Ltd.

Felicamed Biotechnology Co., Ltd.

Xingyu Lin

Yu Chen Zhou

Lewis J Gazzard

Zhonghua Pei

Richard Pastor

Po-Wai Yuen

Firoz Jaipuri

Sanjeev Kumar

Guosheng Wu

Niu Huang

Hima Potturi

Brendan Parr

Yanyan Chu

Joseph P Lyssikatos

Anthony A Estrada

Huifen Chen

Steven Huy Do

Aleksandr Kolesnikov

Matthew Volgraf

Vishal Verma

Elisia Villemure

Rohan V Mendonca

Lan Wang

Jesse Waldo

Daniel Shore

Aijun Lu

Baihua Hu

Yu Zhou

Wendy Liu

Benjamin Douglas Sellers

Guoshen Wu

Powai Yuen

Xiaokai Li

Roheeth Pavana

Venkata Velvadapu

Zuhui Zhang

Tingting Lu

Danni Li

Di Kang

Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 and IDO1 inhibitors

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 Inhibitors

The invention provides novel compounds and compositions comprising a 5-HTantagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HTreceptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

[object Object]

5-HT2B antagonists

Growing community of inventors

Beijing, China

Xingyu Lin